The National Academies of Sciences, Engineering and Medicine
Office of Congressional and government Affairs
At A Glance
 
 
Briefing
: A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report
Dates:
Mon, Mar 27, 2017   2125 Rayburn House Office Bldg. -- 1:30 p.m.
Mon, Mar 27, 2017   835 Hart Senate Office Bldg. – 2:30 p.m.

 

THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE
Health and Medicine Division 
Board on Population Health and Public Health Practice
Committee on a National Strategy for the Elimination of Hepatitis B and C
 
 
*****
 
Congressional Briefings
 
 
on
 
 
A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report
 
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world’s hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide.
 
The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This new report from the National Academies of Sciences, Engineering, and Medicine -- the second of two -- builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.
 
These briefings were for members of Congress and congressional staff only. The report was publicly released on March 28, 2017 and can be found, in its entirety, on the Web site of the National Academies Press.